Page 272 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 272
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
TOP 10% OUTCOMES OF 12-WEEK THERAPY WITH
YI P0874 SIMEPREVIR+SOFOSBUVIR±RIBAVIRIN (SMV+SOF±RBV):
A META-ANALYSIS OF 7 STUDIES AND 715 HCV GENOTYPE
1 (HCV-1) PATIENTS
Brittany E. Yee*, Nghia H. Nguyen, Glen A. Lutchman, Joseph K. Lim,
Mindie H. Nguyen, The United States
TOP 10% PREDICTORS OF SUSTAINED VIRAL RESPONSE TO
YI P0875 4-6 WEEK DURATION THERAPY WITH LEDIPASVIR
+ SOFOSBUVIR + GS-9451 +/- GS-9669 IN EARLY AND
ADVANCED FIBROSIS (NIH/UMD SYNERGY TRIAL)
Sarah Kattakuzhy*, Sreetha Sidharthan, Eleanor Wilson, Angie Price,
Rachel Silk, Chloe Gross, Elizabeth Akoth, Eric Meissner,
Gebremariam Teferi, Veronica Jenkins, Phil Pang, Hongmei Mo,
Anu Osinusi, Henry Masur, Shyamasundaran Kottilil, Anita Kohli,
The United States
TOP 10% SAFETY AND EFFICACY OF SIMEPREVIR/SOFOSBUVIR IN
YI P0876 HEPATITIS C (HCV) INFECTED PATIENTS WITH VARYING
SEVERITY OF CIRRHOSIS: COMPARISON TO MATCHED
ePOSTERS UNTREATED AND PROTEASE INHIBITOR (PI)-TRIPLE
THERAPY TREATED CONTROLS
Varun Saxena*, Lisa Nyberg, Marypat Pauly, Joanna Ready, Jean-
Luc Szpakowski, Barbara Piasecki, Anders Nyberg, Bradley Winston,
Jacquelyn Redd, Lisa Catalli, Aditi Dasgupta, Stephanie Straley,
Kali Sommer, Gayle Witt, Robert Rathbun, Norah Terrault,
The United States
YI P0877 HCV RNA LEVELS ASSESSED AT EARLY STAGES OF
SOFOSBUVIR/RIBAVIRIN DUAL THERAPY IDENTIFY
RELAPSE PATIENTS
Benjamin Maasoumy*, Johannes Vermehren, Caterina Berkowski,
Birgit Bremer, Gavin Cloherty, Dany Perner, Michael P. Manns,
Stefan Zeuzem, Markus Cornberg, Heiner Wedemeyer,
Christoph Sarrazin, Germany
YI P0878 FIRST RIBAVIRIN-FREE SOFOSBUVIR AND SIMEPREVIR
TREATMENT OF HEPATITIS C GENOTYPE 1 PATIENTS
WITH SEVERE RENAL IMPAIRMENT (GFR <30ML/MIN OR
DIALYSIS)
Frank Czul*, Eugene Schiff, Adam Peyton, Cynthia Levy,
Maria Hernandez, Lennox Jeffers, Christopher O’Brien, Paul Martin,
Kalyan R. Bhamidimarri, The United States
272 The International Liver Congress™ 2015 • ILC Programme
TOP 10% OUTCOMES OF 12-WEEK THERAPY WITH
YI P0874 SIMEPREVIR+SOFOSBUVIR±RIBAVIRIN (SMV+SOF±RBV):
A META-ANALYSIS OF 7 STUDIES AND 715 HCV GENOTYPE
1 (HCV-1) PATIENTS
Brittany E. Yee*, Nghia H. Nguyen, Glen A. Lutchman, Joseph K. Lim,
Mindie H. Nguyen, The United States
TOP 10% PREDICTORS OF SUSTAINED VIRAL RESPONSE TO
YI P0875 4-6 WEEK DURATION THERAPY WITH LEDIPASVIR
+ SOFOSBUVIR + GS-9451 +/- GS-9669 IN EARLY AND
ADVANCED FIBROSIS (NIH/UMD SYNERGY TRIAL)
Sarah Kattakuzhy*, Sreetha Sidharthan, Eleanor Wilson, Angie Price,
Rachel Silk, Chloe Gross, Elizabeth Akoth, Eric Meissner,
Gebremariam Teferi, Veronica Jenkins, Phil Pang, Hongmei Mo,
Anu Osinusi, Henry Masur, Shyamasundaran Kottilil, Anita Kohli,
The United States
TOP 10% SAFETY AND EFFICACY OF SIMEPREVIR/SOFOSBUVIR IN
YI P0876 HEPATITIS C (HCV) INFECTED PATIENTS WITH VARYING
SEVERITY OF CIRRHOSIS: COMPARISON TO MATCHED
ePOSTERS UNTREATED AND PROTEASE INHIBITOR (PI)-TRIPLE
THERAPY TREATED CONTROLS
Varun Saxena*, Lisa Nyberg, Marypat Pauly, Joanna Ready, Jean-
Luc Szpakowski, Barbara Piasecki, Anders Nyberg, Bradley Winston,
Jacquelyn Redd, Lisa Catalli, Aditi Dasgupta, Stephanie Straley,
Kali Sommer, Gayle Witt, Robert Rathbun, Norah Terrault,
The United States
YI P0877 HCV RNA LEVELS ASSESSED AT EARLY STAGES OF
SOFOSBUVIR/RIBAVIRIN DUAL THERAPY IDENTIFY
RELAPSE PATIENTS
Benjamin Maasoumy*, Johannes Vermehren, Caterina Berkowski,
Birgit Bremer, Gavin Cloherty, Dany Perner, Michael P. Manns,
Stefan Zeuzem, Markus Cornberg, Heiner Wedemeyer,
Christoph Sarrazin, Germany
YI P0878 FIRST RIBAVIRIN-FREE SOFOSBUVIR AND SIMEPREVIR
TREATMENT OF HEPATITIS C GENOTYPE 1 PATIENTS
WITH SEVERE RENAL IMPAIRMENT (GFR <30ML/MIN OR
DIALYSIS)
Frank Czul*, Eugene Schiff, Adam Peyton, Cynthia Levy,
Maria Hernandez, Lennox Jeffers, Christopher O’Brien, Paul Martin,
Kalyan R. Bhamidimarri, The United States
272 The International Liver Congress™ 2015 • ILC Programme
